Amerisyn, LLC
Quality Generic Pharmaceuticals, Backed by Global Scale.
A U.S. pharmaceutical company offering a growing portfolio of generic medicines across major therapeutic categories.
About Amerisyn
A Growing Generics Company, Built on Established Manufacturing Expertise
Amerisyn, LLC is backed by Senores Pharmaceuticals, a global pharmaceutical manufacturer with FDA-registered facilities, an 80+ product approved ANDA portfolio, and operations spanning more than 40 countries. Amerisyn is part of the Senores family of companies, alongside Havix and Aavis Pharmaceuticals.
We bring that manufacturing depth and product pipeline to the U.S. market, with a growing portfolio of generic medicines across cardiovascular, central nervous system, endocrine, anti-infective, musculoskeletal, and psychiatric categories.
Quality & Manufacturing
Built on a Foundation of Compliance and Quality
Amerisyn's products are manufactured at Senores' FDA-registered, TAA-compliant facility in Atlanta, US. Every product in our portfolio is backed by the same manufacturing standards and quality systems that support Senores Pharmaceuticals’ broader global network.
Why Amerisyn
A Dependable Generics Partner
Quality-Driven Manufacturing
Products manufactured at an FDA-registered, TAA-compliant facility, backed by consistent quality systems across our network.
Backed by Global Scale
Supported by Senores Pharmaceuticals’ international manufacturing network, R&D pipeline, and 80+ approved ANDA portfolio.
Broad, Growing Portfolio
9 molecules across 6 therapeutic categories today, with more added as our pipeline expands.
Reliable Supply
Consistent, dependable supply built to support pharmacies, distributors, and institutional partners alike.
Our Products
A Portfolio Spanning Major Therapeutic Categories
Amerisyn's portfolio includes 9 generic molecules across the categories below, with additional products added as our portfolio grows.
Get In Touch
We’d Love to Hear From You
Whether you’re a pharmacy, distributor, or potential partner, we’d welcome the conversation.